{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T17:49:01Z","timestamp":1760982541149},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1007\/s11883-007-0061-0","type":"journal-article","created":{"date-parts":[[2008,3,15]],"date-time":"2008-03-15T10:28:04Z","timestamp":1205576884000},"page":"454-462","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacotherapy for obesity"],"prefix":"10.1007","volume":"9","author":[{"given":"Lisa M.","family":"Neff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis J.","family":"Aronne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,3,16]]},"reference":[{"key":"61_CR1","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.295.13.1549","volume":"295","author":"C.L. Ogden","year":"2006","unstructured":"Ogden CL, Carroll MD, Curtin LR, et al.: Prevalence of overweight and obesity in the United States, 1999\u20132004. JAMA 2006, 295:1549\u20131555.","journal-title":"JAMA"},{"key":"61_CR2","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1038\/sj.ijo.0802215","volume":"26","author":"J. Vidal","year":"2002","unstructured":"Vidal J: Updated review on the benefits of weight loss. Int J Obes 2002, 26:S25\u2013S28.","journal-title":"Int J Obes"},{"key":"61_CR3","volume-title":"The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults","author":"NHLBI Obesity Education Initiative Working Group","year":"2000","unstructured":"NHLBI Obesity Education Initiative Working Group: The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health\/National Heart, Lung and Blood Institute\/North American Association for the Study of Obesity; October 2000. NIH Publication 00-4084."},{"key":"61_CR4","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/sj.ijo.0801059","volume":"23","author":"D.L. Hansen","year":"1999","unstructured":"Hansen DL, Toubro S, Stock MJ, et al.: The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 1999, 23:1016\u20131024.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"61_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.1550-8528.1998.tb00308.x","volume":"6","author":"B.J. Rolls","year":"1998","unstructured":"Rolls BJ, Shide DJ, Thorwart ML, Ulbrecht JS: Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998, 6:1\u201311.","journal-title":"Obes Res"},{"key":"61_CR6","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/ajcn\/68.6.1180","volume":"68","author":"D.L. Hansen","year":"1998","unstructured":"Hansen DL, Toubro S, Stock MJ, et al.: Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998, 68:1180\u20131186.","journal-title":"Am J Clin Nutr"},{"key":"61_CR7","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archinte.164.9.994","volume":"164","author":"D.E. Arterburn","year":"2004","unstructured":"Arterburn DE, Crane PK, Veenstra DL: The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004, 164:994\u20131003.","journal-title":"Arch Intern Med"},{"key":"61_CR8","doi-asserted-by":"crossref","unstructured":"Padwal R, Li SK, Lau DC: Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2003, 4:CD004094.","DOI":"10.1002\/14651858.CD004094.pub2"},{"key":"61_CR9","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","volume":"356","author":"W.P. James","year":"2000","unstructured":"James WP, Astrup A, Finer N, et al.: Effect of sibutramine on weight maintenance after weight loss: a randomized trial. Lancet 2000, 356:2119\u20132125.","journal-title":"Lancet"},{"key":"61_CR10","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2337\/diacare.28.4.942","volume":"28","author":"R. Vettor","year":"2005","unstructured":"Vettor R, Serra R, Fabris R, et al.: Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care 2005, 28:942\u2013949.","journal-title":"Diabetes Care"},{"key":"61_CR11","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/ajcn\/80.6.1461","volume":"80","author":"B. Hutton","year":"2004","unstructured":"Hutton B, Fergusson D: Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 2004, 80:1461\u20131468.","journal-title":"Am J Clin Nutr"},{"key":"61_CR12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2337\/dc06-0210","volume":"30","author":"B. Richelsen","year":"2007","unstructured":"Richelsen B, Tonstad S, Rossner S, et al.: Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care 2007, 30:27\u201332.","journal-title":"Diabetes Care"},{"key":"61_CR13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"J.S. Torgerson","year":"2004","unstructured":"Torgerson JS, Hauptman J, Boldrin MN, Sj\u00f6str\u00f6m L: Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27:155\u2013161.","journal-title":"Diabetes Care"},{"key":"61_CR14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/oby.2001.79","volume":"9","author":"B. Mittendorfer","year":"2001","unstructured":"Mittendorfer B, Ostlund RE Jr, Patterson BW, Klein S: Orlistat inhibits dietary cholesterol absorption. Obes Res 2001, 9:599\u2013604.","journal-title":"Obes Res"},{"key":"61_CR15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/oby.2000.8","volume":"8","author":"S. R\u00f6ssner","year":"2000","unstructured":"R\u00f6ssner S, Sj\u00f6str\u00f6m L, Noack R, et al.: Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000, 8:49\u201361.","journal-title":"Obes Res"},{"key":"61_CR16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1210\/er.2005-0009","volume":"27","author":"U. Pagotto","year":"2006","unstructured":"Pagotto U, Marsicano G, Cota D, et al.: The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006, 27:73\u2013100.","journal-title":"Endocr Rev"},{"key":"61_CR17","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.2337\/db06-0812","volume":"55","author":"M. Bluher","year":"2006","unstructured":"Bluher M, Engeli S, Kloting N, et al.: Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006, 55:3053\u20133060.","journal-title":"Diabetes"},{"key":"61_CR18","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/35071088","volume":"410","author":"V. Marzo Di","year":"2001","unstructured":"Di Marzo V, Goparaju SK, Wang L, et al.: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410:822\u2013825.","journal-title":"Nature"},{"key":"61_CR19","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/sj.ijo.0802583","volume":"28","author":"C. Ravinet Trillou","year":"2004","unstructured":"Ravinet Trillou C, Delgorge C, Menet C, et al.: CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004, 28:640\u2013648.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"61_CR20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0024-3205(98)00322-1","volume":"63","author":"G. Colombo","year":"1998","unstructured":"Colombo G, Agabio R, Diaz G, et al.: Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 1998, 63:113\u2013117.","journal-title":"Life Sci"},{"key":"61_CR21","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI200523057","volume":"115","author":"D. Osei-Hyiaman","year":"2005","unstructured":"Osei-Hyiaman D, DePetrillo M, Pacher P, et al.: Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005, 115:1298\u20131305.","journal-title":"J Clin Invest"},{"key":"61_CR22","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.amjmed.2007.01.004","volume":"120","author":"S.C. Woods","year":"2007","unstructured":"Woods SC: Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors. Am J Med 2007, 120:S19\u2013S25.","journal-title":"Am J Med"},{"key":"61_CR23","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1038\/sj.ijo.0803276","volume":"30","author":"D. Osei-Hyiaman","year":"2006","unstructured":"Osei-Hyiaman D, Harvey-White J, Batkai S, Kunos G: The role of the endocannabinoid system in the control of energy homeostasis. Int J Obes 2006, 30:S33\u2013S38.","journal-title":"Int J Obes"},{"key":"61_CR24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/sj.ijo.0802847","volume":"29","author":"Y.L. Liu","year":"2005","unstructured":"Liu YL, Connoley IP, Wilson CA, Stock MJ: Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)\/Lep(ob) mice. Int J Obes 2005, 29:183\u2013187.","journal-title":"Int J Obes"},{"key":"61_CR25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1124\/mol.63.4.908","volume":"63","author":"M. Bensaid","year":"2003","unstructured":"Bensaid M, Gary-Bobo M, Esclangon A, et al.: The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa\/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003, 63:908\u2013914.","journal-title":"Mol Pharmacol"},{"key":"61_CR26","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1079\/BJN20041256","volume":"92","author":"P.D. Cani","year":"2004","unstructured":"Cani PD, Montoya ML, Neyrinck AM, et al.: Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. Br J Nutr 2004, 92:757\u2013761.","journal-title":"Br J Nutr"},{"key":"61_CR27","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","volume":"365","author":"L.F. Gaal Van","year":"2005","unstructured":"Van Gaal LF, Rissanen AM, Scheen AJ, et al.: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389\u20131397.","journal-title":"Lancet"},{"key":"61_CR28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","volume":"295","author":"F.X. Pi-Sunyer","year":"2006","unstructured":"Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al.: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761\u2013765.","journal-title":"JAMA"},{"key":"61_CR29","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","volume":"353","author":"J.P. Despres","year":"2005","unstructured":"Despres JP, Golay A, Sjostrom L, et al.: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121\u20132134.","journal-title":"N Engl J Med"},{"key":"61_CR30","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","volume":"368","author":"A.J. Scheen","year":"2006","unstructured":"Scheen AJ, Finer N, Hollander P, et al.: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368:1660\u20131672.","journal-title":"Lancet"},{"key":"61_CR31","doi-asserted-by":"crossref","unstructured":"Curioni C, Andre C: Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006, 4:CD006162.","DOI":"10.1002\/14651858.CD006162.pub2"},{"key":"61_CR32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"W.C. Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393\u2013403.","journal-title":"N Engl J Med"},{"key":"61_CR33","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"D.J. Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696\u20131705.","journal-title":"Lancet"},{"key":"61_CR34","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","volume":"28","author":"R.A. DeFronzo","year":"2005","unstructured":"DeFronzo RA, Ratner RE, Han J, et al.: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092\u20131100.","journal-title":"Diabetes Care"},{"key":"61_CR35","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","volume":"28","author":"D.M. Kendall","year":"2005","unstructured":"Kendall DM, Riddle MC, Rosenstock J, et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083\u20131091.","journal-title":"Diabetes Care"},{"key":"61_CR36","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2337\/diacare.29.02.06.dc05-1267","volume":"29","author":"M.C. Riddle","year":"2006","unstructured":"Riddle MC, Drucker DJ: Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006, 29:435\u2013449.","journal-title":"Diabetes Care"},{"key":"61_CR37","doi-asserted-by":"crossref","unstructured":"Aronne L, Fujioka K, Aroda V, et al.: Progressive reduction in body weight following treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 2007, In press.","DOI":"10.1210\/jc.2006-2003"},{"issue":"Suppl","key":"61_CR38","doi-asserted-by":"crossref","first-page":"167S","DOI":"10.1038\/oby.2004.284","volume":"12","author":"A. Astrup","year":"2004","unstructured":"Astrup A, Toubro S: Topiramate: a new potential pharmacological treatment for obesity. Obes Res 2004, 12(Suppl):167S\u2013173S.","journal-title":"Obes Res"},{"key":"61_CR39","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1345\/aph.1H178","volume":"40","author":"A.L. Tata","year":"2006","unstructured":"Tata AL, Kockler DR: Topiramate for binge-eating disorder associated with obesity. Ann Pharmacother 2006, 40:1993\u20131997.","journal-title":"Ann Pharmacother"},{"key":"61_CR40","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1001\/jama.289.14.1820","volume":"289","author":"K.M. Gadde","year":"2004","unstructured":"Gadde KM, Franciscy DM, Wagner HR, Krishnan KR: Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2004, 289:1820\u20131825.","journal-title":"JAMA"},{"key":"61_CR41","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.4088\/JCP.v67n1209","volume":"67","author":"S.L. McElroy","year":"2006","unstructured":"McElroy SL, Kotwal R, Guerdjikova AI, et al.: Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry 2006, 67:1897\u20131906.","journal-title":"J Clin Psychiatry"},{"key":"61_CR42","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/oby.2002.86","volume":"10","author":"J.W. Anderson","year":"2002","unstructured":"Anderson JW, Greenway FL, Fujioka K, et al.: Bupropion SR enhances weight loss: a 48-week double-blind, placebocontrolled trial. Obes Res 2002, 10:633\u2013641.","journal-title":"Obes Res"},{"key":"61_CR43","doi-asserted-by":"crossref","first-page":"242S","DOI":"10.1038\/oby.2006.317","volume":"14","author":"R.S. Ahima","year":"2006","unstructured":"Ahima RS: Adipose tissue as an endocrine organ. Obesity 2006, 14:242S\u2013249S.","journal-title":"Obesity"},{"key":"61_CR44","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1172\/JCI25977","volume":"115","author":"M. Rosenbaum","year":"2005","unstructured":"Rosenbaum M, Goldsmith R, Bloomfield D, et al.: Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 2005, 115:3579\u20133586.","journal-title":"J Clin Invest"},{"key":"61_CR45","doi-asserted-by":"crossref","unstructured":"Otabe S, Yuan X, Fukutani T, et al.: Overexpression of human adiponectin in transgenic mice results in suppression of fat accumulation and prevention of premature death by high-calorie diet. Am J Physiol Endocrinol Metab 2007, In press.","DOI":"10.1152\/ajpendo.00645.2006"},{"key":"61_CR46","unstructured":"Shionogi announces positive results from a phase IIa study of S-2367, a novel neuropeptide Y5 receptor antagonist for the treatment of obesity [press release]. Florham Park, NJ: Shionogi USA; July 10, 2006."},{"key":"61_CR47","unstructured":"Arena Pharmaceuticals completes enrollment with 3,182 patients in lorcaserin phase 3 BLOOM trial for obesity [press release]. San Diego, CA: Arena Pharmaceuticals; February 5, 2007."},{"key":"61_CR48","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1210\/en.2005-0177","volume":"146","author":"H.M. Hsiung","year":"2005","unstructured":"Hsiung HM, Hertel J, Zhang XY, et al.: A novel and selective beta-melanocyte-stimulating hormone-derived peptide agonist for melanocortin 4 receptor potently decreased food intake and body weight gain in diet-induced obese rats. Endocrinology 2005, 146:5257\u20135266.","journal-title":"Endocrinology"},{"key":"61_CR49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejphar.2004.06.027","volume":"497","author":"T.J. Kowalski","year":"2004","unstructured":"Kowalski TJ, Farley C, Cohen-Williams ME, et al.: Melanin-concentrating hormone-1 receptor antagonism decreases feeding by reducing meal size. Eur J Pharmacol 2004, 497:41\u201347.","journal-title":"Eur J Pharmacol"},{"key":"61_CR50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1172\/JCI30227","volume":"117","author":"D.E. Cummings","year":"2007","unstructured":"Cummings DE, Overduin J: Gastrointestinal regulation of food intake. J Clin Invest 2007, 117:13\u201323.","journal-title":"J Clin Invest"},{"key":"61_CR51","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1210\/jc.2003-030705","volume":"88","author":"D.E. Cummings","year":"2003","unstructured":"Cummings DE, Shannon MH: Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss? J Clin Endocrinol Metab 2003, 88:2999\u20133002.","journal-title":"J Clin Endocrinol Metab"},{"key":"61_CR52","doi-asserted-by":"crossref","first-page":"13226","DOI":"10.1073\/pnas.0605376103","volume":"103","author":"E.P. Zorrilla","year":"2006","unstructured":"Zorrilla EP, Iwasaki S, Moss JA, et al.: Vaccination against weight gain. Proc Natl Acad Sci USA 2006, 103:13226\u201313231.","journal-title":"Proc Natl Acad Sci USA"},{"key":"61_CR53","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1056\/NEJMoa030204","volume":"349","author":"R.L. Batterham","year":"2003","unstructured":"Batterham RL, Cohen MA, Ellis SM, et al.: Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003, 349:941\u2013948.","journal-title":"N Engl J Med"},{"key":"61_CR54","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1210\/jc.2006-1806","volume":"92","author":"I. Gantz","year":"2007","unstructured":"Gantz I, Erondu N, Mallick M, et al.: Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 2007, 92:1754\u201317577.","journal-title":"J Clin Endocrinol Metab"},{"key":"61_CR55","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/sj.ijo.0803344","volume":"30","author":"K. Wynne","year":"2006","unstructured":"Wynne K, Park AJ, Small CJ, et al.: Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes 2006, 30:1729\u20131736.","journal-title":"Int J Obes"},{"key":"61_CR56","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1210\/jc.2003-030421","volume":"88","author":"M.A. Cohen","year":"2003","unstructured":"Cohen MA, Ellis SM, Le Roux CW, et al.: Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003, 88:4696\u20134701.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-007-0061-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-007-0061-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-007-0061-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T19:35:32Z","timestamp":1559417732000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-007-0061-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["61"],"URL":"https:\/\/doi.org\/10.1007\/s11883-007-0061-0","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}